Jw Life Science Corp (234080) — Cash Flow Quality Index
Jw Life Science Corp (234080) has a Cash Flow Quality Index of 0.79x as of December 2025. Operating cash flow of ₩5.08 Billion is below net income of ₩6.45 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore 234080 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Jw Life Science Corp Cash Flow Quality Index (2015–2025)
Historical Cash Flow Quality Index for Jw Life Science Corp across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Jw Life Science Corp (234080) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Jw Life Science Corp (2015–2025)
Year-by-year earnings quality comparison for Jw Life Science Corp. For live market cap and the full company financial profile, see Jw Life Science Corp stock valuation.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.42x | ₩40.54 Billion | ₩28.61 Billion | ▲ +23.0% |
| 2024 | 1.15x | ₩50.69 Billion | ₩43.99 Billion | ▼ -13.7% |
| 2023 | 1.34x | ₩37.57 Billion | ₩28.14 Billion | ▲ +41.4% |
| 2022 | 0.94x | ₩14.13 Billion | ₩14.96 Billion | ▼ -59.6% |
| 2021 | 2.34x | ₩30.17 Billion | ₩12.91 Billion | ▲ +44.6% |
| 2020 | 1.62x | ₩46.75 Billion | ₩28.94 Billion | ▲ +48.8% |
| 2019 | 1.09x | ₩24.28 Billion | ₩22.35 Billion | ▼ -52.4% |
| 2018 | 2.28x | ₩36.13 Billion | ₩15.82 Billion | ▲ +73.8% |
| 2017 | 1.31x | ₩22.05 Billion | ₩16.78 Billion | ▲ +23.9% |
| 2016 | 1.06x | ₩16.08 Billion | ₩15.16 Billion | ▼ -47.3% |
| 2015 | 2.01x | ₩25.90 Billion | ₩12.86 Billion | — |